Table 6.
HR | 95% CI | p Value | |
---|---|---|---|
BPAR at one yr | |||
MPA dose change | |||
Tacrolimus exposure included as a covariable | 2.60 | 1.28–5.29 | 0.008 |
Tacrolimus exposure not included as a covariable | 2.58 | 1.28–5.23 | 0.008 |
Reduced tacrolimus exposure | 0.83 | 0.45–1.53 | 0.545 |
Graft loss at one yr | |||
MPA dose change | |||
Tacrolimus exposure included as a covariable | 2.23 | 1.01–4.89 | 0.047 |
Tacrolimus exposure not included as a covariable | 2.16 | 0.99–4.79 | 0.054 |
Reduced tacrolimus exposure | 1.17 | 0.56–2.44 | 0.684 |
HR, hazard ratio; CI, confidence interval; MPA, mycophenolic acid; BPAR, biopsy-proven acute rejection.
MPA dose change included dose reduction, interruption, or discontinuation.